Edition:
India

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

2.53USD
1:30am IST
Change (% chg)

$-0.30 (-10.60%)
Prev Close
$2.83
Open
$2.78
Day's High
$2.78
Day's Low
$2.51
Volume
38,659
Avg. Vol
69,672
52-wk High
$21.17
52-wk Low
$2.05

Latest Key Developments (Source: Significant Developments)

Sienna Biopharmaceuticals Promotes Alexander Azoy To CFO
Friday, 22 Mar 2019 

March 21 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS PROMOTES ALEXANDER AZOY TO CHIEF FINANCIAL OFFICER AND APPOINTS SEAN ANDREWS TO LEADERSHIP TEAM AS VICE PRESIDENT, INVESTOR RELATIONS.SIENNA BIOPHARMACEUTICALS INC - AZOY WILL SUCCEED JOHN SMITHER AS CFO.  Full Article

Sienna Biopharmaceuticals Reports Q4 Loss Per Share Of $0.93
Thursday, 14 Mar 2019 

March 14 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.93.SIENNA BIOPHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS AS OF DEC. 31, 2018, TOTALED APPROXIMATELY $48.5 MILLION.  Full Article

Arch Venture Fund VIII Reports 19.9 Percent Stake In Sienna Biopharmaceuticals Inc
Thursday, 7 Mar 2019 

March 6 (Reuters) - Sienna Biopharmaceuticals Inc ::ARCH VENTURE FUND VIII REPORTS 19.9 PERCENT STAKE IN SIENNA BIOPHARMACEUTICALS INC AS OF FEB 22 - SEC FILING.  Full Article

Sienna Biopharmaceuticals Says Public Offering Of 8 Mln Common Shares Priced At $2.50 Per Share
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $2.50PER SHARE.  Full Article

Sienna Biopharma Announces Proposed Public Offering Of Common Stock
Wednesday, 20 Feb 2019 

Feb 19 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Sienna Biopharmaceuticals Says Implemented Corporate Restructuring To Focus Co's Resources On SNA-120
Thursday, 3 Jan 2019 

Jan 2 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS - ON JAN 2, IMPLEMENTED CORPORATE RESTRUCTURING TO FOCUS CO'S RESOURCES ON LEAD PRODUCT CANDIDATE, SNA-120 - SEC FILING.SIENNA BIOPHARMACEUTICALS - CORPORATE RESTRUCTURING RESULTED IN REDUCTION IN FORCE TO REDUCE OPERATIONAL COSTS AND PRESERVE CAPITAL.SIENNA BIOPHARMACEUTICALS - RESTRUCTURING WILL RESULT IN ELIMINATION OF 20 POSITIONS, OR ABOUT 34% OF CO'S WORKFORCE.SIENNA BIOPHARMACEUTICALS - RESTRUCTURING IS EXPECTED TO BE SUBSTANTIALLY COMPLETE BY END OF Q1 OF 2019.SIENNA BIOPHARMACEUTICALS - CO'S RESEARCH TEAM BASED IN IVREA, ITALY IS NOT AFFECTED BY RESTRUCTURING.SIENNA BIOPHARMACEUTICALS - ESTIMATES WILL INCUR ONE-TIME EMPLOYEE BENEFITS & SEVERANCE CHARGE OF ABOUT $0.8 MILLION IN Q1 2019 RELATED TO RESTRUCTURING.SIENNA BIOPHARMACEUTICALS - RESTRUCTURING IS EXPECTED TO REDUCE PLANNED OPERATING EXPENSES BY ABOUT 50%, EXCLUDING ONE-TIME CHARGES.  Full Article

Sienna Biopharmaceuticals Announces Plans To Initiate Phase 3 Psoriasis Trials In Second Half Of 2019
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES ITS TOPICAL, NON-STEROIDAL TRKA INHIBITOR SNA-120 (0.05%) DEMONSTRATED SIGNIFICANT IMPACT ON PSORIASIS IN PHASE 2B STUDY AND PLANS TO INITIATE PHASE 3 PSORIASIS TRIALS IN SECOND HALF OF 2019.SIENNA BIOPHARMACEUTICALS INC - SNA-120 WAS WELL TOLERATED WITH FEW TREATMENT-RELATED ADVERSE EVENTS.SIENNA BIOPHARMACEUTICALS INC - SUBJECTS ACHIEVED 58% IMPROVEMENT IN ITCH FROM BASELINE ON I-NRS VERSUS 55% WITH VEHICLE (NOT STATISTICALLY SIGNIFICANT).SIENNA BIOPHARMACEUTICALS INC - 27% OF SUBJECTS ACHIEVED 75% REDUCTION IN PASI SCORE (PASI 75) VERSUS 13% WITH VEHICLE.SIENNA BIOPHARMACEUTICALS INC - 29% OF SUBJECTS ACHIEVED TWO-GRADE IMPROVEMENT ON IGA AND 'CLEAR' OR 'ALMOST CLEAR' SKIN VERSUS 13% WITH VEHICLE.SIENNA BIOPHARMACEUTICALS INC - PHASE 2 STUDY EXPECTED TO BEGIN SECOND HALF 2019.SIENNA BIOPHARMACEUTICALS INC - DID NOT MEET OUR PRIMARY ENDPOINT ON PRURITUS.  Full Article

Sienna Biopharmaceuticals reports third quarter results
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS® REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE $0.82.SIENNA BIOPHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS AS OF SEPT. 30, 2018, TOTALED APPROXIMATELY $64.0 MILLION.  Full Article

Sienna Biopharmaceuticals Reports Results from Study of SNA-125 In Psoriasis
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES RESULTS FROM FIRST-IN-HUMAN STUDY OF SNA-125 IN PSORIASIS AND CONTINUED PROGRESSION TO PHASE 2.SIENNA BIOPHARMACEUTICALS INC - SNA-125 PHASE 2 STUDIES EXPECTED TO BEGIN IN SECOND HALF OF 2019.SIENNA BIOPHARMACEUTICALS INC - SNA-125 PHASE 2 STUDIES EXPECTED TO BEGIN IN SECOND HALF OF 2019.SIENNA BIOPHARMACEUTICALS INC - PHASE 1/2 STUDY DATA OF SNA-125 IN ATOPIC DERMATITIS ON TRACK TO BE RELEASED IN Q4 OF 2018.SIENNA BIOPHARMACEUTICALS - IN MODEL, SNA-125 WAS WELL-TOLERATED AND SHOWED NO SAFETY SIGNALS.SIENNA BIOPHARMA - IN MODEL, ANALYSES SHOWED MODEST, STATISTICALLY SIGNIFICANT REDUCTION WITH SNA-125 0.2 PERCENT IN EPIDERMAL THICKNESS FROM BASELINE.  Full Article

Sienna Biopharmaceuticals May Offer And Sell Shares Of Co's Common Stock Having Offering Price Of Up To $75 Mln
Friday, 24 Aug 2018 

Aug 23 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS-MAY OFFER AND SELL SHARES OF CO'S COMMON STOCK HAVING OFFERING PRICE OF UP TO $75 MILLION FROM TIME TO TIME .  Full Article